Latest news with #BrandonCouillard
Business Insider
13-07-2025
- Business
- Business Insider
Thermo Fisher (TMO) Gets a Buy from Wells Fargo
In a report released on July 11, Brandon Couillard from Wells Fargo maintained a Buy rating on Thermo Fisher, with a price target of $570.00. The company's shares closed last Friday at $434.86. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Couillard covers the Healthcare sector, focusing on stocks such as Exact Sciences, Thermo Fisher, and Maravai Lifesciences Holdings. According to TipRanks, Couillard has an average return of 14.9% and a 60.65% success rate on recommended stocks. In addition to Wells Fargo, Thermo Fisher also received a Buy from Evercore ISI's Vijay Kumar in a report issued on July 8. However, on July 11, Scotiabank downgraded Thermo Fisher (NYSE: TMO) to a Hold. The company has a one-year high of $627.88 and a one-year low of $385.46. Currently, Thermo Fisher has an average volume of 2.74M.
Yahoo
06-07-2025
- Business
- Yahoo
Wells Fargo maintained a Buy rating on Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Brandon Couillard from Wells Fargo maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO) with a price target of $570. Analyst Brandon Couillard noted the recent Amendment to the acquisition deal with Solventum Corp (NYSE:SOLV). The revised agreement excludes Solventum's lower-margin Drinking Water Filtration business from the acquisition, reducing the purchase price from about $4.1 billion to $4.0 billion. Couillard believes that this simplifies the transaction and also potentially accelerates its closing by the end of 2025, while improving the financial attractiveness of the deal. A workstation in a research lab stocked with laboratory products and services. The deal revision is expected to be accretive to Thermo Fisher Scientific Inc.'s (NYSE:TMO) earnings per share even after accounting for financing costs. The exclusion of the non-core Drinking Water business aligns with the focus of the company on higher-margin, higher-growth segments, supporting stronger earnings growth. In addition, Thermo Fisher Scientific Inc. (NYSE:TMO) has demonstrated consistent quarter-over-quarter improvement in core growth, with expectations of about 5% core growth in 2025. Moreover, its long-range plan aims to achieve robust organic growth of 7% to 9%, significant operational margin expansion, and double-digit growth in operating profits. Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading company in the life sciences and diagnostics industry. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
30-06-2025
- Business
- Yahoo
Wells Fargo Remains a Buy on Thermo Fisher (TMO) With a PT of $570
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 11 Best Strong Buy Stocks to Invest in Now. In a report released on June 26, Brandon Couillard from Wells Fargo maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO) with a price target of $570.00. The analyst based the rating on the company's financial prospects and strategic positioning, stating that its recent amendment to the agreement with SOLV is a positive move for the company. A workstation in a research lab stocked with laboratory products and services. The amendment allows Thermo Fisher Scientific Inc. (NYSE:TMO) to exclude the lower-margin Drinking Water Filtration business from the acquisition. The analyst expects this change to potentially expedite the transaction's completion, simplify it significantly, and also reduce the purchase price, factors that boost the deal's financial attractiveness. Couillard further expects the amended deal to be accretive to Thermo Fisher Scientific Inc.'s (NYSE:TMO) EPS, even after factoring in financing costs. The Drinking Water is non-core for the company, which is why the analyst considers its exclusion to be in line with Thermo Fisher Scientific Inc.'s (NYSE:TMO) focus on higher-margin and higher-growth opportunities. Thermo Fisher Scientific Inc. (NYSE:TMO) provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
04-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments. Confident Investing Starts Here: Exact Sciences (EXAS) In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84. According to Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics. Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94. In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03. According to Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
